View ValuationOvation Science 将来の成長Future 基準チェック /06現在、 Ovation Scienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長31.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$76k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$76k free cash flow). Shares are highly illiquid. Negative equity (-CA$1.5m). Revenue is less than US$1m (CA$68k revenue, or US$50k). Market cap is less than US$10m (CA$960.3k market cap, or US$704.9k).Reported Earnings • May 06Full year 2025 earnings released: CA$0.018 loss per share (vs CA$0.013 loss in FY 2024)Full year 2025 results: CA$0.018 loss per share (further deteriorated from CA$0.013 loss in FY 2024). Revenue: CA$67.9k (down 40% from FY 2024). Net loss: CA$631.3k (loss widened 38% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 23Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.005 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$13.6k (down 6.2% from 3Q 2024). Net loss: CA$134.1k (loss narrowed 25% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 21Ovation Science Inc. announced that it has received CAD 0.15835 million in fundingOn October 20, 2025, Ovation Science Inc closed the transaction. The company issued 3,167,000 units at a price of CAD 0.05 per unit for aggregate gross proceeds of CAD 158,350. A director of the company participated in the transaction and acquired 200,000 units. This participation is considered a related party transaction under MI 61-101 but is exempt from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(b), as the value of the transaction is less than 25 per cent of the company's market capitalization. In connection with the offering, the company paid eligible finders a cash fee equal to 8 per cent of the gross proceeds raised from investors they introduced.Buy Or Sell Opportunity • Oct 14Now 33% overvaluedThe stock has been flat over the last 90 days, currently trading at CA$0.035. The fair value is estimated to be CA$0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has grown by 62%.お知らせ • Sep 30Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a non-brokered private placement financing of 4,000,000 units at a price of CAD 0.05 per Unit for proceeds of CAD 200,000 on September 29, 2025. Under the Offering, each unit will consist of one common share and one share purchase warrant. Each Warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a period of 24 months from the date of issue. The Units issued under the Offering will be subject to a statutory hold period of four months and one day from the date of issuance. In connection with the Offering, the Company will pay eligible finders a fee in cash equal to 8% of the gross proceeds raised from persons introduced by the Finder and/or share purchase warrants equal to 8% of the total number of Units subscribed for by persons introduced by the Finder. The broker’s warrants will be exercisable to purchase an additional share at CAD 0.05 per share for a period of 24 months from the date of issue.お知らせ • Sep 29Ovation Science Inc., Annual General Meeting, Nov 25, 2025Ovation Science Inc., Annual General Meeting, Nov 25, 2025.Buy Or Sell Opportunity • Sep 25Now 33% overvaluedOver the last 90 days, the stock has fallen 30% to CA$0.035. The fair value is estimated to be CA$0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has grown by 62%.Reported Earnings • Aug 25Second quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2024)Second quarter 2025 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 2Q 2024). Revenue: CA$16.6k (down 61% from 2Q 2024). Net loss: CA$133.5k (loss widened 76% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Jun 02First quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 1Q 2024)First quarter 2025 results: CA$0.003 loss per share (improved from CA$0.005 loss in 1Q 2024). Revenue: CA$17.5k (down 57% from 1Q 2024). Net loss: CA$121.6k (loss narrowed 31% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • May 07Full year 2024 earnings released: CA$0.013 loss per share (vs CA$0.027 loss in FY 2023)Full year 2024 results: CA$0.013 loss per share (improved from CA$0.027 loss in FY 2023). Revenue: CA$113.2k (up 83% from FY 2023). Net loss: CA$456.2k (loss narrowed 44% from FY 2023). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.007 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.007 loss in 3Q 2023). Revenue: CA$14.5k (up 230% from 3Q 2023). Net loss: CA$178.1k (loss narrowed 7.8% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.New Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$392k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$392k free cash flow). Shares are highly illiquid. Negative equity (-CA$835k). Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (CA$102k revenue, or US$76k). Market cap is less than US$10m (CA$1.06m market cap, or US$783.6k). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).Reported Earnings • Aug 30Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$42.2k (up CA$40.2k from 2Q 2023). Net loss: CA$75.8k (loss narrowed 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Board Change • Aug 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Joan Chypyha was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 23Ovation Science Inc., Annual General Meeting, Sep 20, 2024Ovation Science Inc., Annual General Meeting, Sep 20, 2024.Reported Earnings • May 08Full year 2023 earnings released: CA$0.027 loss per share (vs CA$0.027 loss in FY 2022)Full year 2023 results: CA$0.027 loss per share (in line with FY 2022). Revenue: CA$61.9k (down 55% from FY 2022). Net loss: CA$813.1k (loss widened 2.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • Apr 12Ovation Science Inc. announced that it has received $0.05 million in fundingOn April 11, 2024, Ovation Science Inc closed the transaction.お知らせ • Mar 21Ovation Science Inc. announced that it expects to receive CAD 0.0675 million in fundingOvation Science Inc. announced a private placement of 1,350,000 Units at a price of CAD 0.05 per Unit for a gross proceeds of CAD 67,500 on March 20, 2024. Each unit consists of one common share of the Company and one non-transferable share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of CAD 0.05 per share for a period of 24 months from closing of the private placement. The securities issued under the private placement will be subject to a hold period expiring four months and one day from the date of issuance pursuant to applicable Canadian securities laws and relevant restrictions under the securities laws of other jurisdictions where the placees may be residents.Reported Earnings • Nov 30Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: CA$0.007 loss per share (in line with 3Q 2022). Revenue: CA$4.4k (down 87% from 3Q 2022). Net loss: CA$193.2k (loss narrowed 2.8% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.New Risk • Oct 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$502k). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (CA$113k revenue, or US$83k). Market cap is less than US$10m (CA$1.57m market cap, or US$1.15m). Minor Risk Shareholders have been diluted in the past year (6.8% increase in shares outstanding).お知らせ • Oct 13Ovation Science Inc. announced that it has received CAD 0.2 million in fundingOn October 12, 2023, Ovation Science Inc. closed the transaction. Net proceeds of the offering are CAD 184,000 after payment of commissions totaling CAD 16,000. The Company issued a total of 480,000 brokers warrants.お知らせ • Oct 05Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a proposed private placement of up to 4,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 200,000 on October 3, 2023. Each Unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a two-year term. The Company will pay a commission of 8% cash and 480,000 broker warrants in connection with this offering.Reported Earnings • Sep 02Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)Second quarter 2023 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2022). Revenue: CA$2.0k (down 93% from 2Q 2022). Net loss: CA$262.0k (loss widened 22% from 2Q 2022).Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jul 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jul 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 21Ovation Science Inc., Annual General Meeting, Aug 22, 2023Ovation Science Inc., Annual General Meeting, Aug 22, 2023.Reported Earnings • Jun 03First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (improved from CA$0.007 loss in 1Q 2022). Revenue: CA$40.7k (up 5.5% from 1Q 2022). Net loss: CA$166.0k (loss narrowed 20% from 1Q 2022).Board Change • May 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 07Full year 2022 earnings released: CA$0.027 loss per share (vs CA$0.081 loss in FY 2021)Full year 2022 results: CA$0.027 loss per share (improved from CA$0.081 loss in FY 2021). Revenue: CA$138.2k (down 39% from FY 2021). Net loss: CA$794.1k (loss narrowed 67% from FY 2021).Board Change • Apr 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Dec 01Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2021)Third quarter 2022 results: CA$0.007 loss per share (in line with 3Q 2021). Revenue: CA$34.5k (down 1.1% from 3Q 2021). Net loss: CA$198.8k (loss narrowed 1.9% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 27Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)Second quarter 2022 results: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021). Revenue: CA$29.5k (down 61% from 2Q 2021). Net loss: CA$214.3k (loss widened 4.7% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 26Ovation Science Inc., Annual General Meeting, Oct 27, 2022Ovation Science Inc., Annual General Meeting, Oct 27, 2022.Board Change • Jul 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 31First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.006 loss in 1Q 2021)First quarter 2022 results: CA$0.007 loss per share (down from CA$0.006 loss in 1Q 2021). Revenue: CA$38.6k (down 48% from 1Q 2021). Net loss: CA$208.1k (loss widened 29% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.Board Change • May 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 03Full year 2021 earnings released: CA$0.081 loss per share (vs CA$0.044 loss in FY 2020)Full year 2021 results: CA$0.081 loss per share (down from CA$0.044 loss in FY 2020). Revenue: CA$224.9k (down 70% from FY 2020). Net loss: CA$2.39m (loss widened 102% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.Board Change • May 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 29Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.007 loss per share (up from CA$0.01 loss in 3Q 2020). Revenue: CA$34.9k (down 81% from 3Q 2020). Net loss: CA$202.6k (loss narrowed 20% from 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.Reported Earnings • Sep 02Second quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.025 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: CA$76.3k (down 24% from 2Q 2020). Net loss: CA$204.7k (loss narrowed 67% from 2Q 2020).Reported Earnings • Jun 03First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: CA$73.5k (down 75% from 1Q 2020). Net loss: CA$161.4k (loss widened 46% from 1Q 2020).Reported Earnings • May 03Full year 2020 earnings released: CA$0.044 loss per share (vs CA$0.052 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: CA$750.0k (up 148% from FY 2019). Net loss: CA$1.18m (loss widened 42% from FY 2019).お知らせ • Jan 29Ovation Science Inc. Enters into a Non-Exclusive Distribution Agreement for its DermSafe® Hand Sanitizer with CDMVOvation Science Inc. announced that it has entered into a non-exclusive distribution agreement for its DermSafe® hand sanitizer with CDMV.Is New 90 Day High Low • Jan 16New 90-day low: CA$0.27The company is down 34% from its price of CA$0.40 on 16 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 83% over the same period.Is New 90 Day High Low • Dec 19New 90-day low: CA$0.29The company is down 26% from its price of CA$0.40 on 18 September 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 52% over the same period.Reported Earnings • Dec 03Third quarter 2020 earnings released: CA$0.01 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: CA$181.0k (up 129% from 3Q 2019). Net loss: CA$253.8k (loss widened 80% from 3Q 2019).Is New 90 Day High Low • Dec 01New 90-day low: CA$0.30The company is down 30% from its price of CA$0.43 on 01 September 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 44% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: CA$0.35The company is down 26% from its price of CA$0.47 on 25 June 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.お知らせ • Sep 01Ovation Science Inc. (CNSX:OVAT) acquired World Rights to DermSafe® Hand Sanitizer from Skinvisible, Inc. (OTCPK:SKVI).Ovation Science Inc. (CNSX:OVAT) acquired World Rights to DermSafe® Hand Sanitizer from Skinvisible, Inc. (OTCPK:SKVI) on February 3, 2020. Ovation Science Inc. agreed to pay to Skinvisible a single digit royalty interest on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable. Ovation Science Inc. (CNSX:OVAT) completed the acquisition of World Rights to DermSafe® Hand Sanitizer from Skinvisible, Inc. (OTCPK:SKVI) on February 3, 2020. As of June 15, 2020, the license agreement was revised and it extends the License Agreement indefinitely. In addition to the extension, Ovation will also be transferred two Health Canada Drug Identification Numbers - 02310589 and 02355558, DermSafe trademark; DermSafe clinical data; and the right to patent DermSafe in countries where not currently patented. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ovation Science は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:OVAT - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-100N/A9/30/20250000N/A6/30/20250000N/A3/31/20250000N/A12/31/20240000N/A9/30/20240-100N/A6/30/20240-100N/A3/31/20240-100N/A12/31/20230-100N/A9/30/20230-100N/A6/30/20230-100N/A3/31/20230-1-1-1N/A12/31/20220-1-1-1N/A9/30/20220-2-1-1N/A6/30/20220-2-1-1N/A3/31/20220-2-1-1N/A12/31/20210-2-1-1N/A9/30/20210-1-1-1N/A6/30/20210-1-1-1N/A3/31/20211-1-2-1N/A12/31/20201-1-2-1N/A9/30/20201-1-2-2N/A6/30/20201-1-2-2N/A3/31/20201-1-1-1N/A12/31/20190-1-1-1N/A9/30/20190-1N/A-1N/A6/30/20190-1N/A-1N/A3/31/20190-1N/A0N/A12/31/20180-1N/A0N/A12/31/201700N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: OVATの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: OVATの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: OVATの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: OVATの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: OVATの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: OVATの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 12:02終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ovation Science Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$76k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$76k free cash flow). Shares are highly illiquid. Negative equity (-CA$1.5m). Revenue is less than US$1m (CA$68k revenue, or US$50k). Market cap is less than US$10m (CA$960.3k market cap, or US$704.9k).
Reported Earnings • May 06Full year 2025 earnings released: CA$0.018 loss per share (vs CA$0.013 loss in FY 2024)Full year 2025 results: CA$0.018 loss per share (further deteriorated from CA$0.013 loss in FY 2024). Revenue: CA$67.9k (down 40% from FY 2024). Net loss: CA$631.3k (loss widened 38% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 23Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.005 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$13.6k (down 6.2% from 3Q 2024). Net loss: CA$134.1k (loss narrowed 25% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 21Ovation Science Inc. announced that it has received CAD 0.15835 million in fundingOn October 20, 2025, Ovation Science Inc closed the transaction. The company issued 3,167,000 units at a price of CAD 0.05 per unit for aggregate gross proceeds of CAD 158,350. A director of the company participated in the transaction and acquired 200,000 units. This participation is considered a related party transaction under MI 61-101 but is exempt from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(b), as the value of the transaction is less than 25 per cent of the company's market capitalization. In connection with the offering, the company paid eligible finders a cash fee equal to 8 per cent of the gross proceeds raised from investors they introduced.
Buy Or Sell Opportunity • Oct 14Now 33% overvaluedThe stock has been flat over the last 90 days, currently trading at CA$0.035. The fair value is estimated to be CA$0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has grown by 62%.
お知らせ • Sep 30Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a non-brokered private placement financing of 4,000,000 units at a price of CAD 0.05 per Unit for proceeds of CAD 200,000 on September 29, 2025. Under the Offering, each unit will consist of one common share and one share purchase warrant. Each Warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a period of 24 months from the date of issue. The Units issued under the Offering will be subject to a statutory hold period of four months and one day from the date of issuance. In connection with the Offering, the Company will pay eligible finders a fee in cash equal to 8% of the gross proceeds raised from persons introduced by the Finder and/or share purchase warrants equal to 8% of the total number of Units subscribed for by persons introduced by the Finder. The broker’s warrants will be exercisable to purchase an additional share at CAD 0.05 per share for a period of 24 months from the date of issue.
お知らせ • Sep 29Ovation Science Inc., Annual General Meeting, Nov 25, 2025Ovation Science Inc., Annual General Meeting, Nov 25, 2025.
Buy Or Sell Opportunity • Sep 25Now 33% overvaluedOver the last 90 days, the stock has fallen 30% to CA$0.035. The fair value is estimated to be CA$0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has grown by 62%.
Reported Earnings • Aug 25Second quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2024)Second quarter 2025 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 2Q 2024). Revenue: CA$16.6k (down 61% from 2Q 2024). Net loss: CA$133.5k (loss widened 76% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Jun 02First quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 1Q 2024)First quarter 2025 results: CA$0.003 loss per share (improved from CA$0.005 loss in 1Q 2024). Revenue: CA$17.5k (down 57% from 1Q 2024). Net loss: CA$121.6k (loss narrowed 31% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • May 07Full year 2024 earnings released: CA$0.013 loss per share (vs CA$0.027 loss in FY 2023)Full year 2024 results: CA$0.013 loss per share (improved from CA$0.027 loss in FY 2023). Revenue: CA$113.2k (up 83% from FY 2023). Net loss: CA$456.2k (loss narrowed 44% from FY 2023). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.007 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.007 loss in 3Q 2023). Revenue: CA$14.5k (up 230% from 3Q 2023). Net loss: CA$178.1k (loss narrowed 7.8% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
New Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$392k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$392k free cash flow). Shares are highly illiquid. Negative equity (-CA$835k). Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (CA$102k revenue, or US$76k). Market cap is less than US$10m (CA$1.06m market cap, or US$783.6k). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).
Reported Earnings • Aug 30Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$42.2k (up CA$40.2k from 2Q 2023). Net loss: CA$75.8k (loss narrowed 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Board Change • Aug 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Joan Chypyha was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 23Ovation Science Inc., Annual General Meeting, Sep 20, 2024Ovation Science Inc., Annual General Meeting, Sep 20, 2024.
Reported Earnings • May 08Full year 2023 earnings released: CA$0.027 loss per share (vs CA$0.027 loss in FY 2022)Full year 2023 results: CA$0.027 loss per share (in line with FY 2022). Revenue: CA$61.9k (down 55% from FY 2022). Net loss: CA$813.1k (loss widened 2.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • Apr 12Ovation Science Inc. announced that it has received $0.05 million in fundingOn April 11, 2024, Ovation Science Inc closed the transaction.
お知らせ • Mar 21Ovation Science Inc. announced that it expects to receive CAD 0.0675 million in fundingOvation Science Inc. announced a private placement of 1,350,000 Units at a price of CAD 0.05 per Unit for a gross proceeds of CAD 67,500 on March 20, 2024. Each unit consists of one common share of the Company and one non-transferable share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of CAD 0.05 per share for a period of 24 months from closing of the private placement. The securities issued under the private placement will be subject to a hold period expiring four months and one day from the date of issuance pursuant to applicable Canadian securities laws and relevant restrictions under the securities laws of other jurisdictions where the placees may be residents.
Reported Earnings • Nov 30Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: CA$0.007 loss per share (in line with 3Q 2022). Revenue: CA$4.4k (down 87% from 3Q 2022). Net loss: CA$193.2k (loss narrowed 2.8% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
New Risk • Oct 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$502k). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (CA$113k revenue, or US$83k). Market cap is less than US$10m (CA$1.57m market cap, or US$1.15m). Minor Risk Shareholders have been diluted in the past year (6.8% increase in shares outstanding).
お知らせ • Oct 13Ovation Science Inc. announced that it has received CAD 0.2 million in fundingOn October 12, 2023, Ovation Science Inc. closed the transaction. Net proceeds of the offering are CAD 184,000 after payment of commissions totaling CAD 16,000. The Company issued a total of 480,000 brokers warrants.
お知らせ • Oct 05Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a proposed private placement of up to 4,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 200,000 on October 3, 2023. Each Unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a two-year term. The Company will pay a commission of 8% cash and 480,000 broker warrants in connection with this offering.
Reported Earnings • Sep 02Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)Second quarter 2023 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2022). Revenue: CA$2.0k (down 93% from 2Q 2022). Net loss: CA$262.0k (loss widened 22% from 2Q 2022).
Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jul 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jul 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 21Ovation Science Inc., Annual General Meeting, Aug 22, 2023Ovation Science Inc., Annual General Meeting, Aug 22, 2023.
Reported Earnings • Jun 03First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (improved from CA$0.007 loss in 1Q 2022). Revenue: CA$40.7k (up 5.5% from 1Q 2022). Net loss: CA$166.0k (loss narrowed 20% from 1Q 2022).
Board Change • May 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 07Full year 2022 earnings released: CA$0.027 loss per share (vs CA$0.081 loss in FY 2021)Full year 2022 results: CA$0.027 loss per share (improved from CA$0.081 loss in FY 2021). Revenue: CA$138.2k (down 39% from FY 2021). Net loss: CA$794.1k (loss narrowed 67% from FY 2021).
Board Change • Apr 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Dec 01Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2021)Third quarter 2022 results: CA$0.007 loss per share (in line with 3Q 2021). Revenue: CA$34.5k (down 1.1% from 3Q 2021). Net loss: CA$198.8k (loss narrowed 1.9% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 27Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)Second quarter 2022 results: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021). Revenue: CA$29.5k (down 61% from 2Q 2021). Net loss: CA$214.3k (loss widened 4.7% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 26Ovation Science Inc., Annual General Meeting, Oct 27, 2022Ovation Science Inc., Annual General Meeting, Oct 27, 2022.
Board Change • Jul 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 31First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.006 loss in 1Q 2021)First quarter 2022 results: CA$0.007 loss per share (down from CA$0.006 loss in 1Q 2021). Revenue: CA$38.6k (down 48% from 1Q 2021). Net loss: CA$208.1k (loss widened 29% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
Board Change • May 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 03Full year 2021 earnings released: CA$0.081 loss per share (vs CA$0.044 loss in FY 2020)Full year 2021 results: CA$0.081 loss per share (down from CA$0.044 loss in FY 2020). Revenue: CA$224.9k (down 70% from FY 2020). Net loss: CA$2.39m (loss widened 102% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
Board Change • May 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 29Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.007 loss per share (up from CA$0.01 loss in 3Q 2020). Revenue: CA$34.9k (down 81% from 3Q 2020). Net loss: CA$202.6k (loss narrowed 20% from 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Sep 02Second quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.025 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: CA$76.3k (down 24% from 2Q 2020). Net loss: CA$204.7k (loss narrowed 67% from 2Q 2020).
Reported Earnings • Jun 03First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: CA$73.5k (down 75% from 1Q 2020). Net loss: CA$161.4k (loss widened 46% from 1Q 2020).
Reported Earnings • May 03Full year 2020 earnings released: CA$0.044 loss per share (vs CA$0.052 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: CA$750.0k (up 148% from FY 2019). Net loss: CA$1.18m (loss widened 42% from FY 2019).
お知らせ • Jan 29Ovation Science Inc. Enters into a Non-Exclusive Distribution Agreement for its DermSafe® Hand Sanitizer with CDMVOvation Science Inc. announced that it has entered into a non-exclusive distribution agreement for its DermSafe® hand sanitizer with CDMV.
Is New 90 Day High Low • Jan 16New 90-day low: CA$0.27The company is down 34% from its price of CA$0.40 on 16 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 83% over the same period.
Is New 90 Day High Low • Dec 19New 90-day low: CA$0.29The company is down 26% from its price of CA$0.40 on 18 September 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 52% over the same period.
Reported Earnings • Dec 03Third quarter 2020 earnings released: CA$0.01 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: CA$181.0k (up 129% from 3Q 2019). Net loss: CA$253.8k (loss widened 80% from 3Q 2019).
Is New 90 Day High Low • Dec 01New 90-day low: CA$0.30The company is down 30% from its price of CA$0.43 on 01 September 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 44% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: CA$0.35The company is down 26% from its price of CA$0.47 on 25 June 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
お知らせ • Sep 01Ovation Science Inc. (CNSX:OVAT) acquired World Rights to DermSafe® Hand Sanitizer from Skinvisible, Inc. (OTCPK:SKVI).Ovation Science Inc. (CNSX:OVAT) acquired World Rights to DermSafe® Hand Sanitizer from Skinvisible, Inc. (OTCPK:SKVI) on February 3, 2020. Ovation Science Inc. agreed to pay to Skinvisible a single digit royalty interest on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable. Ovation Science Inc. (CNSX:OVAT) completed the acquisition of World Rights to DermSafe® Hand Sanitizer from Skinvisible, Inc. (OTCPK:SKVI) on February 3, 2020. As of June 15, 2020, the license agreement was revised and it extends the License Agreement indefinitely. In addition to the extension, Ovation will also be transferred two Health Canada Drug Identification Numbers - 02310589 and 02355558, DermSafe trademark; DermSafe clinical data; and the right to patent DermSafe in countries where not currently patented.